CNTX - NASDAQ

Context Therapeutics Inc.

Context Therapeutics Inc.

CNTXยทNASDAQ

$2.05

-15%
HealthcareBiotechnology

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$188.35M
EPS-0.3800
P/E Ratio-5.39
Earnings Date08/05/2026
Context Therapeutics Inc.

Context Therapeutics Inc. Fair Value Envelope

CNTX ยท NASDAQ

Our analysis suggests that CNTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.05, this represents a potential HIDDEN relative to our calculated worth for Context Therapeutics Inc..

HIDDEN
Intrinsic Value
Current Price: $2.05

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$290.5M
+ Cash & Equivalents$66.0M
Firm Value-$224.5M
- Debt$112.1K
Equity Value-$224.6M
/ Shares Outstanding89,704,194B
DCF Value-$3
OVERVALUED BY 222%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$29.0M
-$31.9M
-$35.0M
-$38.5M
-$42.3M
-$46.4M
-$51.0M
-$56.0M
-$61.6M
-$67.7M
Maintenance CapEx
-$7.5K
-$8.2K
-$9.0K
-$9.9K
-$10.9K
-$11.9K
-$13.1K
-$14.4K
-$15.8K
-$17.4K
Owner Earnings
-$29.0M
-$31.9M
-$35.0M
-$38.5M
-$42.3M
-$46.4M
-$51.0M
-$56.1M
-$61.6M
-$67.7M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$26.9M
-$27.3M
-$27.8M
-$28.3M
-$28.8M
-$29.3M
-$29.8M
-$30.3M
-$30.8M
-$31.3M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your CNTX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.